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Mapping Allele-Specific DNA Methylation:
A New Tool for Maximizing Information from GWAS
Benjamin Tycko1,*
In this issue of The Journal, an article by Schalkwyk et al.1 shows the landscape of allele-speciﬁc DNA methylation (ASM) in the human
genome. ASM has long been studied as a hallmark of imprinted genes, and a chromosome-wide version of this phenomenon occurs, in
a random fashion, during X chromosome inactivation in female cells. But the type of ASM motivating the study by Schalkwyk et al. is
different. They used a high-resolution, methylation-sensitive SNP array (MSNP) method for genome-wide proﬁling of ASM in total
peripheral-blood leukocytes (PBL) and buccal cells from a series of monozygotic twin pairs. Their data bring a new level of detail to our
knowledge of a newly recognized phenomenon—nonimprinted, sequence-dependent ASM. They document the widespread occurrence
of this phenomenon among human genes and discuss its basic implications for gene regulation and genetic-epigenetic interactions. But
this paper and recent work from other laboratories2,3 raises the possibility of a more immediate and practical application for ASM
mapping, namely to help extract maximum information from genome-wide association studies.Genome-wide association studies
(GWAS) have been tremendously
successful in localizing candidate
genes for susceptibility to common
diseases, but they are now coming up
against two technical roadblocks: First,
most (~90%) of the suprathreshold
disease-association signals are at non-
coding SNPs.4–6 Among these statis-
tical signals, which ones are due to
bona ﬁde functional regulatory SNPs
(rSNPs), and how can these rSNPs be
identiﬁed? Nowadays, by following
GWAS to identify a SNP-tagged chro-
mosomal region of interest, investiga-
tors resequence the region to identify
all of the variants, and from there
they seek to prioritize which ones
might be functional. But when a non-
synonymous coding change is still
not found, the essential problem
remains. Second, because of multiple
comparisons, the threshold for sig-
niﬁcance needs to be set stringently,
typically at p < 107 or p < 5 3 108,
so there are numerous subthreshold
peaks that are difﬁcult to interpret.
Are some of these signals true positives
that should not be discarded? This
question can be partly addressed by
meta-analyses across multiple GWAS,
and in silico predictive methods are
also promising.7 But a more direct
approach would be to combine statis-
tical genetic evidence from GWAS1Institute for Cancer Genetics and Taub Institute, D
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ence of rSNPS. There is good reason
to think that such evidence can be
provided by the type of mapping
shown in the Schalkwyk et al. paper,
with the use of the strategy dia-
grammed here in Figure 1.
This idea has a strong precedent in
studies of a related phenomenon—
allele-speciﬁc RNA expression (ASE).
In the simplest scenario, ASE, also
called the allelic transcript ratio or
ATR, can be measured by comparing
relative levels of allelic transcripts
within a sample by using gene-speciﬁc
RT-PCR followed by conventional
sequencing, Pyrosequencing, or SNaP-
shot assays, with PCR products from
genomic DNA used as the standard
for equal biallelic representation. This
approach of cDNA-gDNA comparison
has been a workhorse tool since the
early 1990s in labs studying imprinted
genes,8 and it was adapted in 2002 by
Yan et al. to search for ASE in a set of
nonimprinted genes.9 In their brief
report, they described ASE (> 30%
expression bias between the two
alleles) in 6/13 genes examined, three
of these genes showing ASE in > 10%
of heterozygous individuals tested.
They used lymphoblastoid cell lines
from two Centre d’E´tude du Polymor-
phisme Humain (CEPH) families to
show that the ASE for two genesepartment of Pathology, Columbia University Medi
erican Society of Human Genetics. All rights reserve
The American Journal of Human Gen(PKD2 [MIM 173910] and CAPN10
[MIM 605286]) was transmitted as a
Mendelian trait with the same allele
relatively repressed in each informa-
tive family member, suggesting a role
for cis-acting regulatory polymor-
phisms in dictating the ASE.
Shortly thereafter, several labs
applied this type of analysis, or related
methods correlating net mRNA ex-
pression with genotypes, in much
larger genome-wide surveys.10–19
Recently, Verlaan et al. carried out
ASE analysis on primary RNA tran-
scripts by using both high-throughput
conventional sequencing and 454/
FLX massively parallel sequencing,
thereby gaining access to informative
intronic SNPs, which substantially
increased the number of informative
samples.20 As a tool for ﬁnding and
validating rSNPs, measuring ASE has
the major advantage of being inter-
nally controlled, comparing expres-
sion of the two alleles within one
individual rather thanmeasuring asso-
ciations of SNP genotypes with net
expression of the gene across subjects,
which can suffer from the limited
precision of Q-PCR and microarray
assays and unpredictable effects
of environmental and trans-acting
inﬂuences. Still, both approaches are
valid, and assessing correlations of
haplotypes with net transcript levelscal Center, New York, NY 10032, USA
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Figure 1. Sequence-Dependent ASM as a Tool for Extracting Maximum Information from GWAS
(A) In genomic imprinting, the ASM is established in gametogenesis and dictated by the parental origin of the allele, with weak or absent
effects of local haplotypes. Some imprinted genes show hypermethylation on the paternal allele as shown here, whereas others show
hypermethylation of the maternal allele. In successive generations, the imprint is erased and then reset appropriately in gametogenesis,
according to the sex of the transmitting parent. Thus genomic imprinting is non-Mendelian. In contrast, SNP- or haplotype-dependent
ASM is dictated in cis by the local DNA sequence, regardless of parent of origin. This type of ASM is transmitted in a Mendelian fashion,
and its presence is an indication of nearby regulatory SNPs that function, by mechanisms still largely unknown, to confer the allelic
asymmetry. Although the number of imprinted genes is reasonably well established, the number of genes with nonimprinted,
sequence-dependent ASM is inﬂuenced both by tissue type and by the stringency of the cutoffs utilized for scoring the allelic asymmetry.
Black circles indicate methylated CpG dinucleotides; white circles, unmethylated CpGs. IC denotes imprinting center.
(B) Schema for extracting maximum information from GWAS by overlapping association signals with data frommapping ASM and ASE.
Most GWAS signals, even if they are true positives, are not likely to be the most important functional SNP, but rather serve to tag a func-
tional rSNP nearby, which can confer ASE and/or ASM. Thus, genomic regions scoring as positive by both criteria (suprathreshold or
subthreshold statistical associations in GWAS and ASE or ASM by appropriate assays) are likely to be true positives harboring bona
ﬁde causal rSNPs. Avoiding false positives will require using stringent criteria for recurrent genotype-dependent ASE and ASM and
validating the high-throughput data from microarrays or Nextgen sequencing by independent locus-speciﬁc assays.arguably gets more directly at the bio-
logically relevant outcome. From all
of these studies, sufﬁcient information
is now available to allow general
conclusions as to the frequency of
ASE and the extent towhich the allelic
expression bias is dictated by cis-acting
DNA polymorphisms. In all studies so
far, the vast majority of ASE can be
accounted for by cis-effects. Estimates
of the frequency of ASE vary strongly,
depending on the cutoff utilized for
the strength of the expression bias
and according to the types of cell lines
or primary tissues examined; with
moderately stringent thresholds, the
frequency in some cell types can be
up to 30% of genes surveyed.21 Find-
ing the strongest and most-speciﬁc
rSNPs will depend on examinining
the bona ﬁde biological target tissues
of a given disease and setting the
threshold for ASE more stringently.
Using the genuine target tissue for
analysis is critically important, be-110 The American Journal of Human Geneticscause it is already clear that genotype-
dependent mRNA expression can be
highly tissue speciﬁc.19 For some
diseases, such as type 2 diabetes melli-
tus (T2D [MIM#125853]), deciding on
the critical target tissue will not be
easy.22
As an important adjunct to these
studies, Stranger et al. used transcrip-
tome proﬁling in lymphoblastoid
lines from individuals included in
HapMap to sort out the relative
contributions of SNPs and copy-
number variants to interindividual
differences in gene expression. They
found that, although both SNPs and
CNVs contributed, the majority of
genotype-dependent expression vari-
ation (84%) in these cells was attribut-
able to SNPs, which were not acting as
surrogates for the CNVs.23
There is an interesting technical
caveat in studying ASE, stemming
from the curious phenomenon of
random (mosaic) monoallelic expres-86, 109–112, February 12, 2010sion (RME), which can be observed at
certain loci on autosomes24–28 and
can sometimes correlate with ASM.27
As pointed out by a recent study using
X chromosome inactivation as a
marker for clonality, a substantial
percentage of human lymphoblastoid
lines (from 1% to 25%, depending on
the source) are nearly monoclonal.29
This clonal predominance can artifac-
tually eliminate the randomness of
RME, which can then be mistaken for
ASE. Methods to monitor and correct
for this problem have been developed
and successfully applied,21 but now
that the necessary methodologies for
genome-wide proﬁling have been
established with the use of lympho-
blastoid lines as a renewable source of
RNA, it is likely that future studies
will be able to use mostly primary cells
and tissues.
Beyond providing evidence for
rSNPs being near a gene of interest,
can mapping ASE help to close in on
the precise positions of these func-
tional SNPs? Proof of principle is start-
ing to appear, and several examples
(not intended to be a complete list)
are useful to consider here. Forton
et al. found recurrent ASE of the IL13
(MIM 147683) gene in lymphoblas-
toid cells and then used DNA from
CEPH families to map the most
strongly correlated SNPs, which
turned out to be clustered 250 kb
upstream of this gene.30 Another
example was reported by Schadt
et al., who surveyed the genotype
dependence of mRNA expression in
human livers and aligned their data
on putative cis-acting rSNPs with
statistically signiﬁcant signals from
multiple GWAS for type 1 diabetes
mellitus (T1D [MIM %222100]),
thereby arriving at the conclusion
that RPS26 (MIM 603701), SORT1
(MIM 602458), and CELSR2 (MIM
604265) are strong candidates for
inﬂuencing T1D susceptibility.18 Sub-
sequently, Ge et al. generated a
genome-wide map of ASE-associated
SNPs by using cDNA-gDNA com-
parisons on high-density Illumina
Human1M BeadChips. They tested
for associations of haplotypes with
the strength of the allelic expression
imbalance and zeroed in on a 16 kb
regulatory haplotype causing relative
overexpression of FAM167A (MIM
610085; also known as C8orf13) and
relative underexpression of its neigh-
boring, autoimmune-disease-associ-
ated gene, BLK (MIM 191605).21 In
an even more recent study, Heap
et al. used Nextgen RNA sequencing
(RNA-Seq) for genome-wide character-
ization of ASE in human T cells from
four healthy individuals.15 They gen-
erated 20 million uniquely mapping
45 bp reads per sample and arrived at
an estimate of about 4.6% of heterozy-
gous SNPs showing an allelic repre-
sentation bias in T cell RNA. They
conﬁrmed their conclusions for three
loci by using gene-speciﬁc assays of
PCR/cloning and direct sequencing
comparing cDNA versus genomic
DNA. Although not among the genes
chosen for independent validations,
an interesting locus with ASE via the
primary sequencing data was CD6(MIM 186720)—a candidate suscepti-
bility gene for multiple sclerosis (MS
[MIM #126200]) from prior GWAS.
Given these already successful
outcomes of using ASE to ﬁnd rSNPs,
can mapping ASM make a useful
contribution? DNA is a more stable
molecule than RNA, andDNAmethyl-
ation is easily and unambiguously
scored by bisulﬁte sequencing. More-
over,measurementsmade on genomic
DNA average evenly over the entire
cell population and cannot be domi-
nated by rare cells or cell types, as can
happen with RNA expression. Last
but not least, labs studying human
genetics simply have more freezers
full of DNA than of RNA. Therefore,
mapping ASM and overlapping the
data with genome-wide association
signals is an attractive concept. The
new study by Schalkwyk et al. has
much to say about this possibility.1
As background to their paper, an
important initial proof-of-principle
study was done by Kerkel et al., who
used MSNP on Affymetrix 250K StyI
SNP arrays to examine several human
tissues, including PBL, hematopoietic
stem cells, and placenta . Their study
identiﬁed recurrent ASM on various
human chromosomes outside of im-
printed loci and uncovered a strong
correlation of this phenomenon with
local SNP genotypes.2 That paper was
quickly followed by several other
reports, including a study by Zhang
et al., who used extensive bisulﬁte
sequencing of PBL DNA to document
SNP-dependent ASM in CpG-rich
sequences in or near four genes on
human chromosome 21.3 In both of
these studies, when sequence-depen-
dent ASMwas present at a given locus,
its dependence on the genotype at
closely adjacent SNP(s) was close to
absolute. Extending this phenom-
enon to the well-controlled mouse
model system, Schilling et al. did a
genome-wide analysis inmacrophages
from two common laboratory strains
(C57BL/6 and BALB/c). They found
that ASM was frequent and widely
distributed across the genome and
that the allelic asymmetry in DNA
methylation was largely attributable
to cis-acting polymorphisms.31 TheThe American Journal of Human Genavailability of dense SNP arrays for
analyzing genetic variation in mice
should facilitate more studies along
these lines with even higher sample
throughput.32
Enter the Schalkwyk et al. study,
which presents the landscape of ASM
inhumanPBL at sufﬁcientlyhigh reso-
lution to warrant overlapping their
gene lists with statistical peaks from
GWAS. As noted above, they used
MSNP on higher-density Affymetrix
6.0 SNP arrays for genome-wide
proﬁling of ASM in blood leukocytes
and buccal cells. They independently
validated each of ten examples among
the ‘‘hits’’ with ASM by using bisulﬁte
conversion followed by SNaPshot
assays. Not surprisingly, they con-
ﬁrmed ASM at several of the loci re-
ported in the earlier study by Kerkel
et al., but with the higher-resolution
method they were able to compile a
much larger list of candidate loci,
which their validations strongly
suggest are mostly true positives. As is
often the case in genomics papers,
one of their most useful tables is in the
online data, namely Table S3, which
shows thatmore than 150ASM-associ-
ated SNPs, distributed across each of
the human chromosomes, are signiﬁ-
cantly associated with the expression
of nearby genes. It will also be useful
to follow the convergence of data
from independent studies of ASE and
ASM; encouragingly, in the Schalkwyk
et al. paper, a number of loci with ASM
are also represented among the genes
found to show ASE in the survey by
Ge et al.21 So, from this and each of
the other recent studies, ASM seems
to be frequently, though not always,
linked to ASE.
How can this ﬁeld move forward?
There are still clear limitations to all
the available data sets: MSNP relies
on methylation-sensitive restriction
sites and does not survey all CpG
dinucleotides. Also, microarray-based
methods are limited by the annoying
fact that only a subset of all SNPs is
‘‘chipable.’’ Microarrays, particularly
those with custom designs, will still
be very useful for high sample
throughput, but Nextgen bisulﬁte
sequencing will inevitably becomeetics 86, 109–112, February 12, 2010 111
the way to go for analyzing fewer
samples at deﬁnitive single-base-pair
resolution, ultimately eliminating
false negatives from incomplete
genomic coverage.33
Lastly, a good part of what we know
about DNA methylation comes from
work in cancer epigenetics, from
which we know that most cancers
have an altered epigenome, with
gains of promoter methylation acting
as an alternative to somatic mutation
in inactivating tumor suppressor
genes.34 In this context, another
possibility with potentially broad
applications will be opened up by
studies combining GWAS and ASM
mapping, namely that certain alleles,
deﬁned by SNPs, indels, and CNVs,
may be more susceptible to becoming
hypermethylated in the initiation and
progression of human neoplasia. Spe-
ciﬁc evidence to this effect has already
been produced by several labs, in-
cluding those of Kang et al., who
reported an association of p14ARF
(CDKN2A [MIM 600160]) polymor-
phisms with the tendency of this gene
to become methylated in colorectal
cancers,35 Murrell et al., who found
an association of IGF2 (MIM 147470)
SNPs or haplotypes with Beckwith-
Wiedemann syndrome (BWS [MIM
#130650]),36 and Boumber et al., who
showed that an indel polymorphism
in the PDLIM4 gene (MIM 603422,
also known as RIL) affects the propen-
sity of this gene to becomemethylated
in leukemia and colon cancer.37
Web Resources
The URL for data presented herein is as
follows:
Online Mendelian Inheritance in Man
(OMIM), http://www.ncbi.nlm.nih.gov/
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